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Abstract 
The pharmaceutical industry has been struggling against problems related with 
drugs with low solubility as this is a very limiting factor in the development of drug 
products. Co-crystals are solid forms known for a very long time although they have not 
been fully explored in their potentialities. Co-crystals can be defined as crystalline 
homogenous structures composed of two or more compounds, held together by 
noncovalent bonds, usually hydrogen bonds, and solid at room temperature. These 
structures can change the physicochemical properties of drugs, like solubility, dissolution 
rate, stability and particle properties, which could be interesting for the drug development 
process. It is still difficult to identify the optimal co-crystallization method for each 
situation and typically this process is evaluated on a case-by-case basis. Reported 
studies show that the most commonly used method is solvent evaporation. However, the 
main drawback of solvent evaporation is the scale-up difficulty. Therefore, this work 
explored milling as an alternative method. This method can more easily be scaled-up. 
This work is based on the co-crystallization of glibenclamide, a sulfonylurea used in the 
treatment of non-insulin-dependent diabetes mellitus. Glibenclamide is categorized as a 
class II drug (low solubility, high permeability) by the Biopharmaceutical Classification 
System. The formation of co-crystals was attempted with six different co-formers – 
adenine (ADE), nicotinamide (NICO), malic acid (MAL), mannitol (MAN), p-
aminobenzoic acid (PABA) and tromethamine (TRIS). The grinding assisted co-
crystallization method was performed on a ball mill. Grinding products were 
characterized by differential scanning calorimetry and vibrational spectroscopy (near and 
mid-infrared) and compared with glibenclamide, co-formers and physical mixtures. It was 
concluded that the most suitable co-formers for the formation of a glibenclamide co-
crystals were MAL, PABA (without solvent) and TRIS. 
 
 
 
 
 
 
 
 
 
Key-words: pharmaceutical co-crystals; glibenclamide; ball milling; vibrational 
spectroscopy; differential scanning calorimetry. 
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Resumo 
A indústria farmacêutica tem ao longo do tempo enfrentado problemas 
relacionados com a fraca biodisponibilidade de muitos fármacos, nomeadamente os 
integrantes de formas orais. Muitos destes problemas estão relacionados com a baixa 
solubilidade ou fraca velocidade de dissolução. A abordagem para minimização de 
problemas relacionados com estes fatores tem sido muito variada, e estão 
documentadas várias abordagens físicas e químicas. Neste contexto, a produção de co-
cristais, ou co-cristalização, é uma técnica de alteração de estado sólido e tem 
apresentado resultados vantajosos relativamente à melhoria da solubilidade de 
fármacos. Os co-cristais são formas sólidas homogéneas compostas por duas ou mais 
moléculas, contidas numa única estrutura cristalina, sendo sólidos à temperatura 
ambiente. Tais compostos apresentam uma estequiometria bem definida e estão ligados 
entre si através de ligações não-covalentes, normalmente pontes de hidrogénio. 
Existem várias metodologias para produção de co-cristais sendo que as mais utilizadas 
(p.e., evaporação por solvente) têm desvantagens ao nível da transposição de escala e 
por isso dificuldade de utilização a uma escala de produção. A opção de produção de 
co-cristais por moagem tem sido documentada ao longo dos últimos anos embora não 
seja ainda uma técnica muito utilizada e por isso ainda razoavelmente desconhecida em 
termos do seu potencial, nomeadamente no que respeita à pureza dos co-cristais 
obtidos assim como o impacto que as condições de fabrico têm nos co-cristais. Esta 
tese pretende aumentar o conhecimento na área da produção de co-cristais pela técnica 
de moagem, nomeadamente aferindo a sua capacidade em produzir co-cristais com 
caraterísticas de pureza adequadas fazendo a ponte com outros métodos como a 
evaporação de solvente. A glibenclamida foi o fármaco selecionado como caso de 
estudo. Está categorizado como um fármaco de classe II pelo Sistema de Classificação 
Biofarmacêutica, isto é, apresenta baixa solubilidade e elevada permeabilidade. Tal 
fármaco é uma sulfonilureia utilizada para o tratamento da diabetes mellitus, sendo esta 
uma doença do foro metabólico, caracterizada por níveis elevados de açúcar no sangue 
(hiperglicemia), exibindo duas categorias etiopatogénicas: diabetes mellitus tipo 1 ou 
auto-imune e diabetes mellitus tipo 2 ou não-dependente de insulina. A diabetes mellitus 
tipo 2 afeta mais de 9% da população mundial, sendo que as opções terapêuticas de 
primeira-linha incluem a administração de metformina (biguanida), numa fase inicial, à 
qual se equaciona a simultaneidade com sulfonilureias (por exemplo, glibenclamida) 
com o agravamento da condição.  
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A produção de co-cristais de glibenclamida nesta tese foi executada através do 
método de co-cristalização por moagem utilizando um moinho de bolas. O fármaco alvo 
foi testado em combinação com seis potenciais co-formadores distintos: adenina, 
nicotinamida, ácido málico, manitol, ácido p-aminobenzóico e trometamina. Os testes 
foram realizados utilizando 1mmol de fármaco e de potencial co-formador utilizando 
duas bolas de moagem de 12mm durante 3 horas a uma velocidade de 600 rpm. Os os 
produtos obtidos foram caracterizados quanto a propriedades de estado sólido por 
calorimetria diferencial de varrimento e por espectroscopia de infravermelho médio e 
infravermelho-próximo quanto ao seu perfil químico. Tendo em conta que, em princípio, 
um co-cristal apresenta características físicas e químicas diferentes dos precursores, 
todos os produtos obtidos após moagem foram caracterizados em comparação com a 
glibenclamida, respectivo potencial co-formador e mistura física de ambos. Verificou-se 
que no caso da nicotinamida e manitol não se obtiveram co-cristais. No sistema 
envolvendo adenina verificaram-se alterações nos espetros de infravermelho, embora 
esses resultados não fossem confirmados através de uma alteração visível do perfil de 
calorimetria térmica. A utilização de ácido p-aminobenzóico revelou também resultados 
promissores indicados por todas as técnicas analíticas usadas.  Os sistemas que 
sobressaíram por apresentarem resultados bastante conclusivos relativamente à 
formação de co-cristais nestas condições envolveram os co-formadores ácido málico e 
trometamina. Os resultados obtidos pelo método de moagem encontram-se em linha 
com os obtidos por evaporação de solvente descritos na literatura. A utilização de 
condições de moagem diferentes, nomeadamente no que respeita à velocidade e 
tipologia das esferas de moagem deverá no futuro ser avaliada consistentemente para 
que sejam identificadas zonas ótimas de operação para produção de co-cristais, tendo 
em vista o rendimento e a sua pureza. 
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Chapter 1 – Introduction 
1.1 – Drug development 
The goal of pharmaceutical development is to design the best drug product 
possible and corresponding manufacturing process. The information obtained from 
pharmaceutical development studies provides scientific knowledge to support the 
establishment of the design space, specifications and manufacturing controls. (1,2) The 
development of a new medicinal product from a new compound is a complex procedure 
which involves different disciplines and can be broken down into five distinct stages: 
discovery and development, preclinical research, clinical research, drug review and post-
market drug safety monitoring. Table 1 summarizes the main activities that occur at each 
stage. (3–6)  
 
Table 1. Stages of drug development and respective activities.  
Stages of drug development Activities 
Discovery and development 
Several compounds may be potential candidates for 
development as a medical treatment. After identifying a 
promising compound for development, studies are 
conducted to gather information on: 
• how it is absorbed, distributed, metabolized and 
excreted; 
• best dosage and mechanism of action; 
• side effects and how it interacts with other drugs; 
• its effectiveness as compared with similar drugs. 
Preclinical research 
Studies are conducted to find out whether the drug has 
toxicity. These studies must provide detailed information 
on dosing and toxicity levels. 
At the end of this stage, it must be decided if the drug 
should be tested in people. 
Clinical research 
Drug developers must submit an investigational new drug 
(IND) application and then wait for the approval to begin 
the clinical trials. Clinical trials involve several phases: 
Phase I – lasts several months and aims to know if the 
drug is safe and its dosage. This phase encompasses 
studies related to: 
• pharmacokinetic, which studies the time course of 
drug absorption, distribution, metabolism, and 
excretion; 
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• pharmacodynamic, which studies the relationship 
between drug concentration at the site of action and 
the resulting effect, including the time course and 
intensity of therapeutic and adverse effects; 
• pharmacovigilance, which studies the activities 
relating to the detection, assessment, 
understanding and prevention of adverse effects or 
any other drug-related problem; 
• tolerability, which represents the degree to which 
adverse effects can be tolerated by the patient. 
Phase II -  lasts from several months to 2 years and aims 
to identify side effects and efficacy; 
Phase III – lasts from 1 to 4 years and aims to monitoring 
adverse reactions and its efficacy; 
Phase IV – the purpose of this phase is to study the safety 
and the efficacy of the tested drug. 
Drug review 
If after preclinical and clinical research, the drug in 
question presents evidence of being safe and effective, it 
can be filed an application to market the drug. 
Post-market drug safety 
monitoring 
At the time of the market approval, there is not a complete 
information about the safety of the drug. Therefore, the 
true picture of a product`s safety evolves over the years 
that make up a product`s lifetime in the marketplace. So, 
it is essential to monitoring the drug safety after the market 
approval. 
 
1.2 – Solid Forms 
One paramount procedure during the early stages of drug development is the 
screening and selection of existing solid state of the drug (or active pharmaceutical 
ingredient (API)) due to the fact that it may influence the API’s physicochemical, 
mechanical properties and chemical stability. As solids, APIs can exist in crystalline or 
amorphous structures. However, the pharmaceutical industry is keener on the crystalline 
forms due to their characteristics which include superior stability, ease of purification, 
being their low solubility the major drawback. Amorphous forms have a higher mobility 
and energy state, which give them a higher solubility, but they have low stability and tend 
to recrystallize over time. The latter, make amorphous materials less appealing for the 
pharmaceutical industry. (7–9) 
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As crystalline forms are more attractive to the pharmaceutical industry, a more 
detailed analysis will be given.  
 
1.2.1 – Crystalline solids 
Crystalline solids can exist in the form of polymorphs, solvates/hydrates, salts and 
co-crystals. (10) 
Polymorphs exist when the drug substance crystallizes in different crystal packing 
arrangements, all of which having the same elemental composition. Physicochemical 
properties, such as solubility, melting point and crystal shape, vary with the polymorphic 
form, so it is extremely important to screen polymorphs for pharmaceutical applications. 
(10–13) Thus, the fact that polymorphs exhibit different characteristics is an advantage 
for their use. However, the major drawback is that the properties can change in such a 
way that the compound ceases to be pharmacologically active. (14) 
 
Solvates often called pseudo-polymorphs due to the presence of the solvent 
molecules in the crystal lattice, are multiple component crystals, where the crystallization 
solvent is entrapped in the host lattice. These compounds have as a particularity the fact 
that one of the components is liquid at room temperature. When the liquid component is 
water, the solvate is called a hydrate. (2,3,5,6) The presence of solvent molecules 
influences the intermolecular interactions, thereby conferring different physical and 
chemical properties, such as thermodynamic properties and solubility, from those of the 
unsolvated form. Due to the solvent molecule, which can be lost during processing, 
solvates are typically viewed as a problem by the pharmaceutical industry. (14,15) 
Solid 
Crystalline Amorphous 
Single 
co
Multiple 
comp
Salt Molecular      
adduct 
Co-crystal Solvate 
Hydrate 
Polymorph 
Pseudo-polymorphs 
Figure 1. Schematic representation of solid forms. 
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Most drug molecules on the market are salts and, usually, salts readily undergo 
crystallization leading to a resulting material which facilitates the subsequent processing. 
Thus, salt formation has become a widely used technique to increase both the dissolution 
rate and solubility of pharmaceutical drugs. A salt is a multicomponent system formed 
by an acid-base reaction between the API and an acidic or basic substance by proton 
transfer from acid (A) to base (B). (8,16–18) Although salts are widely used, the formation 
of salts is inadequate for non-ionizable drugs, which is an obvious disadvantage. (15,17) 
Considering that all mentioned crystalline forms present disadvantages for the 
pharmaceutical industry, other alternatives might be considered. One of such 
alternatives may assume the form of co-crystals. 
1.2.1.1 – Co-crystals 
About 40 to 70% of drugs screened in industrial research have poor solubility and 
such problem led the pharmaceutical scientists to try to find a solution towards a drug 
with better solubility, dissolution rate and, hence, bioavailability. Co-crystallization allows 
to improve the API’s physicochemical properties without changing its structure, thus, API 
activity remains intact. (12,19–22) The definition of co-crystals is still debated in the 
scientific literature, as the Food and Drug Administration (FDA) states that “co-crystals 
are a dissociable multicomponent solid crystalline supramolecular complex which 
contains two or more components within the same crystal lattice wherein the components 
are in neutral state and interact via non-ionic interactions” and European Medicines 
Agency (EMA) states that “co-crystals are in general defined as homogenous crystalline 
structures made up of two or more components in a definite stoichiometric ratio where 
the arrangement in the crystal lattice is not based on ion pairing”. Despite this, the 
scientific community agrees that co-crystals enhance the bioavailability (are more 
soluble and stable) and do not affect its pharmacological action. In addition to these 
benefits, it can be introduced through the co-former, additional nutritional and health 
benefits. Co-crystals are held together by noncovalent interactions, usually hydrogen 
bonds due to their strength and directionality. Regarding the co-crystal formation, if 
ΔpKa>3 then salt formation is expected, yet if ΔpKa<1 there will be less than substantial 
proton transfer resulting in co-crystal formation. In instances where the difference in pKa 
values is between 1 and 3, the extent of proton transfer is usually not predictable and 
spectroscopic tools may be needed to probe the extent of ionization and therefore the 
location in the co-crystal/salt continuum.(12,16,23–25) 
Regarding co-crystals development, studies have reported an enhancement in the 
dissolution rate. For example, GBL and oxalic acid (1:2) system determined an 
enhancement from 12% to 50% when compared to the pure API and GBL and 
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tromethamine (1:1) system determining an increase from 11% to 29% when compared 
with the pure drug. (26) Other examples that demonstrate the success of the co-crystal 
approach in enhancing properties of drugs are regarding the antifungal agent 
itraconazole, in which co-crystals of itraconazole-malic acid (Sporanox®) show a higher 
solubility and a faster dissolution rate, carbamazepine: saccharin co-crystals have shown 
an increasing of the carbamazepine bioavailability, the piracetam: tartaric acid co-
crystals showed improved hygroscopic properties. Also, the dissolution rate of 
exemestane-megestrol and exemestane-maleic acid co-crystals were improved when 
using the co-crystallisation method. (16,22,23,27,28) Furthermore, in the last years 
several drugs were studied in order to obtain a co-crystal and the number of studied 
drugs for this purpose have been increasing, being estimated that the number of studied 
co-crystals will increase over the next years. (29) The last decade witnessed expedition 
of co-crystals from bench to successful drug products. Successfully marketed co-crystals 
products include Suglat® (ipragliflozin-proline), Entresto® (valsartan-sacubitril), 
Sporanox® (itraconazole-malic acid) and Steglujan® (ertugliflozin-sitagliptin), to prevent 
hyperglycaemia in type 2 diabetes mellitus. In addition, few combinations are in various 
stages of clinical trials, such as tramadol hydrochloride−celecoxib and TAK 020-gentisic 
acid. (27,30–32) 
 
Co-former selection 
Design of pharmaceutical co-crystals can be defined as the combination of 
theoretically and experimentally strategies employed to obtain the best co-crystal 
product. It is an approach that should be initiated by a drug complete characterization, 
followed by the selection of co-formers and the co-crystallization method. Considering 
that one of the aims of co-crystallization is to improve the solubility of the drug, it is 
necessary to realize the importance of co-former selection, since its solubility will be 
correlated with the solubility of the co-crystal. (33,34) 
One of the main challenges in pharmaceutical co-crystal development is the 
selection of co-formers that are compatible with the designated drug and do not affect its 
pharmacological activity.  Also, co-formers must be non-toxic and present no adverse 
side effects, reason why, co-formers should be approved as generally regarded as safe 
(GRAS). A crystal of an organic compound is the ultimate supermolecule and its 
assembly is achieved through hydrogen bonds between the individual molecules. In the 
structure of a crystal, during the regular repetition of crystal patterns, the pattern of 
interactions can be called a supramolecular synthon. They can be classified as: (24,35) 
• Supramolecular homosynthons: made up of identical self-complementary 
functional groups; 
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• Supramolecular heterosynthons: made up of different but complementary 
functional groups.  
 
"Trial and error" is still a widely used technique to choose co-formers, but in recent 
years, different approaches have been used using for example the Cambridge structural 
database (CSD), a repository for small molecule crystal structures. This platform allows 
the search for ordered, error-free organic crystal structures and incomplete or unreliable 
structures are filtered out. The remaining structures are exported to another software for 
further molecular statistical analysis. Thus, distribution models are constructed on 
parametric and nonparametric correlation coefficients between pairs of descriptors, such 
as simple atoms and bonds, resulting in the most probable final co-crystal structure. (20–
22,34) This approach can be very efficient when it comes to relatively strong interactions, 
however, when it comes to comparing the strengths between different types of specific 
intermolecular interactions, like Van der Walls forces, it may be almost impossible due 
to the dependence of the energy of interactions on interatomic distances in different 
types of intermolecular interactions. (36) Moreover, for big molecules, the contribution of 
dispersion and electrostatic interactions to the total energy of interaction may be 
comparable to the energy of specific interactions. The only solution towards solving this 
issue is the application of comparative quantum-chemical calculations, determining the 
basic structural motifs (BSM) of a crystal. By applying this approach, it is possible to 
describe the structure of molecular crystals by a directional rhombus from molecule or 
molecular complex as a crystal-building unit for the three-dimensional structure of the 
crystal. This way, supramolecular synthons can be divided into four groups:  (36,37) 
• Local or basic – leading to the formation of molecular complexes; 
• Primary – responsible for the formation of a BSM of the crystal;  
• Secondary – providing the packing of BSMs; 
• Auxiliary – depending on energies of the interactions between molecules.  
Another approach includes the evaluation of the Hansen solubility parameters 
(HSP), which is used to predict the miscibility of a drug with the co-former. Such 
prediction is based on the premise that materials with similar solubility parameters are 
Figure 2. Examples of supramolecular synthons: (i) Homosynthon formed between amide 
dímer; (ii) Heterosynthon formed between carboxylic acid group and amide group. 
( (
(i)(i) (i)   (i)(i) (ii)   
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miscible. Having this in mind, the total cohesive energy is divided into three individual 
components: dispersion, polar and H-bonding. HSP are used to compare the distance 
between two molecules (Ra): as smaller the distance is, the more likely the two 
molecules are to be compatible. Relative energy difference (RED) is given by combining 
the Ra with the interaction radius with the solvent. With this in mind: (36,37) 
• If RED<1, the molecules are alike and will dissolve; 
• If RED=1, the system will partially dissolve; 
• If RED>1, the system will not dissolve. 
The above-mentioned methods to assist co-crystals design and co-former 
selection can be used individually or combined.  
 
In view of the studies already carried out on co-crystals, it is possible to address 
which co-formers are most used. Carboxylic acids have been studied as a co-former 
most extensively, which is due to the carboxylic acid moieties are one of the most 
commonly studied functional groups in crystal engineering. Examples of already studied 
combinations with carboxylic acid co-formers and APIs are caffeine-oxalic acid, 
fluoxetine hydrochloride-benzoic acid, itraconazole-malic acid and norfloxacin-maleic 
acid. Besides carboxylic acids, amides and alcohols are also mostly used as a co-former: 
ibuprofen-nicotinamide, baicalein-nicotinamide and dexlansoprazole-sorbitol, for 
example. (28,38–44) 
1.3 – Co-crystallization techniques 
A co-crystallization technique can be defined as any technique that allows 
combining two or more molecules, API and co-former in this case, through non-covalent 
interactions in a crystallization process. The selection of the suitable co-crystallization 
technique is of utmost importance to ensure appropriate co-crystal/particle properties, 
such as purity and particle size. To the pharmaceutical industry, it is also important that 
the co-crystallization technique can be easily scaled-up. (45,46) One possible 
classification towards co-crystallization techniques is related to the usability of solvent, 
being classified as solvent-based or solvent-free methods. Solvent-based methods are 
the most studied on a laboratory scale. (14) Therefore, they are the most common and 
well understood from a scientifically and technological perspective. Solvent-based 
methods are mainly used due to their simplicity and the possibility of process monitoring, 
but the fact that these methods are usually not scalable and the use of large amounts of 
hazardous solvents are huge disadvantages. On the other hand, solvent-free methods 
are less studied, but the co-crystals are produced in the absence of solvents, or by using 
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negligible amounts, and the excellent quality and purity, the fast processing times and 
the high throughputs make these methods a great deal with substantial industrial interest. 
(46,47) 
 
1.3.1 – Mechanochemical methods 
A mechanochemical reaction is a chemical reaction induced by the direct 
absorption of mechanical energy and the mechanochemical reactive sites are typically 
generated by methods such as grinding, stretching and shearing. Such methods have 
become increasingly attractive regarding the production of co-crystals, in particular by 
milling, since they can be applied to a wide range of compounds and are solvent-free. 
(14) 
1.3.1.1 – Neat grinding method 
Neat grinding, solid-state grinding or dry grinding, is based on mixing stoichiometric 
co-crystal components together in the solid state and grinding them manually by using a 
mortar and pestle, or mechanically by using a ball mill or vibratory mill. Since manual dry 
grinding has some problems with reproducibility, mechanical methods should be used to 
obtain a more efficient co-crystallization. (47) When using a ball mill for neat grinding, 
the components are loaded into a rotating chamber partially filled with small balls which 
can be of stainless steel, tungsten carbide or zirconium oxide, for example, and are 
subsequently mixed. (14) Depending on the driving-force, co-crystallization methods can 
be classified as thermodynamic or kinetic methods. In this case, neat grinding is 
considered a kinetic method, which involves non-equilibrium conditions, depending on 
the system energy and, correspondingly, to reaction duration. (14) Neat grinding has 
been a rising technique in the co-crystallization field and several studies have been 
successfully reported. For example piracetam-citric acid and piracetam-tartaric acid co-
crystals (48), carbamazepine-nicotinamide co-crystal (49), carbamazepine–saccharin 
co-crystal (50), indomethacin-saccharin co-crystal (51) and ethenzamide-saccharin co-
crystal (52). 
Although mechanochemical methods are still less common, they offer advantages 
such as being environmentally friendly due to the absence of solvents and can be 
performed at room temperature. Despite the many advantages, a huge drawback with 
this solvent-free method, with no heating stage involved, is related with the energy 
required for the co-crystallization of compounds, often not enough. (47) Therefore, in 
some cases, the use of a small quantity of solvent can accelerate the process because 
the solvent acts as a catalyst increasing the kinetics of the process known as liquid-
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assisted grinding (LAG). The systems piracetam-citric acid and piracetam-tartaric acid 
were used to compare LAG and neat grinding to produce co-crystals and it was 
concluded that both systems produced co-crystals through both methods, however, the 
LAG method produced co-crystals faster. (48) This fact can be explained by the increase 
in the possibility of molecular collisions and the increase in degrees of orientation and 
conformational freedom, leading to a kinetic improvement. It is not clear why LAG is more 
efficient compared with neat grinding, but this method provides other benefits over dry 
grinding, such as product crystallinity, ability to control polymorph formation and higher 
yield. (48,53) 
 
1.4 – Pharmaceutical co-crystals manufacturing 
Several co-crystallization techniques were described in the literature, however, not 
all of them can be considered for industrial purposes due to scale-up limitations. Scaling-
up a method from laboratory scale to industrial production is a process that cannot 
compromise the product quality nor its characteristics. Regarding the techniques used in 
the pharmaceutical industry, spray drying is widely used for particle engineering and it is 
a technique easy to scale up to produce co-crystals. Despite being a technique relatively 
easy to scale up, further studies on how this technique can be used to produce co-
crystals are still needed. A relatively new technique, spray congealing, is another 
technique that can be used for co-crystals production in industrial scale.  However, 
because it is a fairly recent technique, more studies are needed to better understand this 
technique. Hot melt extrusion (HME) is a broadly studied technique in the co-crystals 
field and it is a promising technique for the industrial production of co-crystals. HME is a 
relatively simple technique and the reported studies have shown that it produces co-
crystals with good quality. (14,54–56) 
1.4.1 – Product development and process monitoring 
Quality of the final product is extremely important for the pharmaceutical industry 
and, nowadays, the concept of quality control is overcome by embedding the product 
quality from the beginning of its development, through design strategies. Product 
development can be approached in various ways and the applicant can either choose an 
empirical approach or a systematic approach, or even a combination of both. Quality-by-
design (QbD) appears as a systematic approach and it is defined as “a systematic 
approach to development that begins with predefined objectives and emphasizes 
product and process understanding and process control, based on sound science and 
quality risk management” by the International Conference on Harmonisation (ICH). 
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Moreover, QbD is found in optimization and understanding of how the design of a product 
and its manufacturing process can affect the final product quality. (2,14,57–59) Due to 
the necessity of building the quality into the product, a deep control and understanding 
of the manufacturing process are needed. Thus, process analytical technology (PAT) 
can provide the tools to deepen the knowledge of the manufacturing process. The ICH 
defines PAT as “a system for designing, analysing, and controlling manufacturing 
through timely measurements of critical quality and performance attributes of raw and in-
process materials and processes with the goal of ensuring final product quality”, being 
PAT recommend by FDA and EMA. PAT is boosted to assist QbD implementation by 
reducing risks to regulatory and quality concerning while improving efficiency. (2,57–59) 
QbD concepts and PAT tools have already been used to design and monitor co-
crystallization techniques. However, due to their simplicity and the possibility of easily 
integrate PAT tools, most of the monitored techniques were solvent-based techniques. 
PAT tools increase process understanding while monitoring co-crystallization processes 
and can aid the scale-up process. So, to achieve co-crystals with desired quality, real-
time monitoring can be an added value allowing process optimization at all stages to be 
accomplished. (2,14,60) 
1.4.2 – Co-crystals continuous manufacturing  
Currently, most industrial co-crystallization manufacturing processes adopted the 
batch processing mode. However, batch production encompasses disadvantages, such 
as multiple sequential steps and interruptions, which is not favourable for scale-up, 
consumption of raw materials and requirement of extensive validation. So, continuous 
manufacturing emerged as an alternative to batch mode, also in the co-crystallization 
field. Continuous manufacturing has many advantages when compared to the batch 
mode because it is simple to scale-up and allows a more automated way of 
manufacturing. (14,61,62) Carbamazepine - trans-cinnamic acid co-crystals, (61) and 
carbamazepine-nicotinamide co-crystals were produced in lab-scale in continuous mode 
by spray-drying (62). Vertex Pharmaceuticals has already adopted continuous 
manufacturing to produce Orkambi® (lumacaftor-ivacaftor), a drug product to target 
cystic fibrosis. (23,61) In the pharmaceutical industry, continuous manufacturing is still 
recent and its use for co-crystallization processes is very scarce. Despite that, the 
interest in shifting from batch manufacturing to continuous is markedly increasing. 
(14,64,65) 
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1.5 – Characterization methods 
It is essential in co-crystallization studies to confirm phase transformation and to 
characterize co-crystal product(s). Thus, it is of paramount importance to apply the 
appropriate characterization methods to select the most promising co-crystal candidates. 
Regarding the characterization techniques, powder x-ray diffraction (PXRD), differential 
scanning calorimetry (DSC) and vibrational spectroscopy are the most used. (22,66,67) 
PXRD is a technique that detects changes in the crystal lattice, providing fundamental 
structural information about a co-crystal formation. This technique is mainly used since 
different crystalline phases show distinctly different PXRD patterns. Regarding the DSC 
technique, it is based on the heating of binary physical mixtures of the complex drug- co-
former and the fact that it is not a time-consuming technique makes DSC a widely used 
approach for co-crystal detection. Both near- and mid-infrared spectroscopy methods 
are broadly used for co-crystallization detection regarding vibrational spectroscopy. 
Near-infrared spectroscopy (NIR) can give physical and chemical information, however 
mid-infrared spectroscopy (MIR) is a technique that gives more information because it 
provides information on the molecular structure. (68–70) 
1.5.1 – Differential scanning calorimetry 
Differential scanning calorimetry (DSC) is a thermoanalytical technique that has 
been reported as a simple and rapid approach towards co-crystal screening. DSC is 
based on the heating of the two potential co-crystal components, beyond the eutectic 
point.(14,68) The use of this technique assumes that the melting point of the co-crystal 
differs from that of forming components, which is confirmed with the fact that in more 
than 50% of the cases, co-crystals showed a lower melting point compared with both 
components. When analysing a DSC scan, co-crystallization is considered possible if an 
endothermic peak associated with the eutectic melting is followed by an exothermic 
peak, corresponding to the co-crystal formation (Fig. 3a). Co-crystallization is considered 
not possible when an endothermic peak representing the eutectic melting is present 
together with further peaks revealing melt or degradation points of the individual 
compounds (Fig. 3b). (68,71) 
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It was reported how DSC can be important regarding co-former selection because 
from selecting a co-former with a melting point greater or lesser than the API, it is 
possible to raise or lower the melting point of the co-crystal. A reported article, in which 
a drug was studied with several co-formers, has shown that the melting point of the final 
drug depends on the chosen co-former. (72) 
1.5.2 – Powder x-ray diffraction 
Powder x-ray diffraction (PXRD) is a paramount technique for the study of 
crystalline solid-state materials since this technique detects changes in the crystal lattice. 
This technique allows to verify whether there are new links between API and co-former 
through the existence of new peaks in the PXRD pattern. In the case of new links, it is 
required to determine together with other techniques if the formation of a co-crystal 
actually occurred. (69,70) Although this technique is widely used to verify the formation 
of co-crystal, a disadvantage is the long measurement times. (69,70) 
 
1.5.3 – Vibrational spectroscopy 
Vibrational spectroscopic methods, such as near-infrared (NIR) and mid-infrared 
(MIR) spectroscopy are two important techniques for co-crystals characterization. The 
NIR spectral region is defined from 780 to 2500nm, which comprises combination and 
overtone bands, the strongest being of OH, CH, NH and SH groups, and it is usually 
measured in the reflectance mode on powder samples. Due to the fact that this technique 
has a low energy, no pre-treatment is needed for the sample because the signal will 
never be saturated. NIR is a powerful technique giving information of physical (e.g. 
particle size through scattering) and chemical properties and regarding co-crystal 
characterization, the spectrum of the sample is usually compared to the physical mixture 
spectrum. In the case of new vibrational bands, it may indicate the formation of new links 
Figure 3. Examples of DSCs: (a) DSC in which co-crystallization is possible and (b) DSC in which co-
crystallization is not possible.  
(a) (b) 
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between the API and co-former, i.e., a co-crystal might have been formed. The 
implantation of NIRs as a PAT tool for the on-line monitoring of co-crystallization was 
already studied and reported (22) and the fact that NIR can be successfully used as a 
PAT tool is very appealing to the pharmaceutical industry. (70) In Figure 4, the correlation 
chart used for the NIR spectra results interpretation is displayed.(29) 
 
MIR spectral region is defined from 2500 to 25000nm and the vibrational transitions 
occur at distinct wavelengths, which depends on the molecular structure of the 
compound. This technique has been widely applied in a pharmaceutical setting and in 
the last decade, it has been used to characterize co-crystals because if there is a new 
vibration if there is a new existing vibration it may indicate that the co-crystal was formed. 
One major advantage of this technique in the pharmaceutical field is that samples can 
be measured in different states, i.e., liquid, solid or gas. (14,74) In Figure 5 the correlation 
chart used for the MIR spectra results interpretation is displayed. (29) 
Figure 4. Major absorption bands found on NIR spectra.  
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Although both techniques highlight different co-crystal characteristics, for a 
detailed characterization it is necessary to use several techniques at the same time and, 
thus obtaining more information about the newly formed product. 
1.6 – Diabetes mellitus 
Diabetes mellitus is defined as a group of metabolic diseases characterized by 
increased blood glucose levels (hyperglycaemia), mainly caused by a deficient insulin 
action on target tissues. Diabetes mellitus typical symptoms involve polyuria, polydipsia, 
weight loss, polyphagia and blurred vision. (29,75–77) Diabetes mellitus can be 
categorized in two different etiopathogenetic categories: (29,75,76) 
• Diabetes mellitus type 1: an autoimmune disease, which represents 
approximately 10% of the total diagnosed diabetic population; 
• Diabetes mellitus type 2: non-insulin-dependent, which represents 90% of the 
total diagnosed diabetic population. 
Diabetes mellitus type 2 is caused either by a mechanism of insulin, which is 
triggered by an insensitivity of glucose-utilizing tissues to insulin due to a progressive 
loss of ꞵ-cell function (which primary function is to store and release insulin) in the 
pancreas or by a relative impairment in the insulin secretion process. Its incidence has 
been increasing worldwide due to environmental factors, unhealthy eating habits, 
sedentary lifestyle and stress. As a result, Diabetes mellitus type 2 is considered one of 
the biggest epidemic diseases of the twenty-first century. (29,75,78–80)  The treatment 
for Diabetes mellitus type 2 is divided in two ways: a lifestyle management and drug 
therapy. For drug therapy treatment, there are several main drugs prescribed: (79,81–
83)  
Figure 5. Major absorption bands found on MIR spectra. 
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• Sulfonylureas (glipizide, glibenclamide, gliclazide, glimepiride) improve glucose 
homeostasis by stimulating insulin secretion on b-cells; 
• Biguanides (metformin) decrease hepatic glucose production; 
• Alpha-glucosidase inhibitors (acarbose, voglibose, miglitol) decrease 
carbohydrate absorption. 
Besides these therapies, there are also incretin-based therapies composed of 
glucagon-like peptide-1 analogues or receptor agonists, dipeptidyl-peptidase-4 
inhibitors, thiazolidinediones, and newest classes such as sodium-glucose 
cotransporter-2 inhibitors. (82,83) 
1.6.1 – Sulfonylureas 
Sulfonylureas (SU) hypoglycemic activity was discovered during the Second World 
War when an SU derivate p-amino benzene sulfonamide-isopropyl thiodiazole was 
tested as a typhoid fever treatment. The patients who received that treatment suffered 
from convulsion and coma, which are only reversed by glucose administration. (84–86) 
SU are classified into two different generation, according to their appearance: 
• First generation such as acetohexamide, tolbutamide, chlorpropamide and 
tolazamide; 
• Second generation such as glibenclamide, gliclazide, glimepiride and glipizide. 
Regarding both generations, they are mostly differentiated by the potency of their 
correspondent agents, being the second generation of SU more potent than the first.  
Noninsulin-dependent diabetes mellitus treatment using SU is restricted to the second-
generation agents because the first-generation agents marked toxicity combined with 
long half-lives and high protein bounding, but low albumin affinity, increase the risk of 
drug interactions. (87,88) In comparison with other antidiabetic drugs, SU display fast 
onset of action and generics availability reduces its cost. On the other hand, SU 
disadvantages include weight gain and increased risk of hypoglycaemic, mainly 
glibenclamide (GBL).  
Mechanism of action 
SU are insulin secretagogues, acting by stimulating insulin release from ꞵ-cells of 
the pancreas to the plasma, leading that the effectiveness of this drug depends on the 
presence of residual pancreatic-ꞵ-cells. SU mechanism of action involves the binding, 
and respective blockage, of the sulfonylurea type 1 receptor subunit (SUR1) of the ATP-
sensitive potassium channels (K(ATP)) on the pancreatic-ꞵ-cells plasma membrane. The 
formed complex, SU-SUR1(K(ATP)) prevents the inward current flow of potassium ions 
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(K+) within the ꞵ-cell and induces calcium ions (Ca2+) influx through voltage-sensitive 
calcium channels, which trigger the exocytosis of insulin.  (84,89) 
After the aforementioned mechanism, SU increase insulin secretion, which takes 
place as insulin granules are translocated to the ꞵ-cells membrane. Later, in the second 
phase, the mechanism only happens if ꞵ-cell function is preserved, involving the 
progressive formation of new insulin granules. The risk of severe hypoglycaemia is a 
serious disadvantage, which occurs due to the independence of the mechanism to blood 
glucose levels. (84,89) 
 
Figure 6. Scheme of sulfonylurea mechanism of action. 
1.6.1.1 – Glibenclamide 
Glibenclamide (GBL) or glyburide is a sulphonamide urea derivate with 
antihyperglycemic activity, which belongs to the sulfonylureas antidiabetic 
pharmaceutical class of compounds. As a solid, GBL appears as a white or an almost 
white crystalline powder, which is insoluble in water (4mg/L at 27ºC), leading to poor 
dissolution rate and subsequent decrease of its gastrointestinal absorption, slightly 
soluble in alcohol and freely soluble in dichloromethane. GBL chemical structure and 
formula are represented in Figure 7. (26,89–91) 
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In Table 2, physicochemical properties of GBL are displayed. From these 
parameters, GBL is considered insoluble in water and from the pKa value it is possible 
to state that the absorption occurs in stomach and initial duodenum portion. (89,89,91) 
Table 2. Physicochemical properties of GBL. 
API 
Water solubility 
(mg/L) 
BCS class pKa logP 
Melting 
point (°C) 
Glibenclamide 4.0 II 
4.32 
(strongest 
acidic) 
-1.2 
(strongest basic) 
4.70 169 
 
About GBL pharmacodynamics, it lowers blood glucose acutely by stimulating the 
release of insulin from the pancreas. On type 2 patients with chronic administration, the 
blood glucose lowering effect persists despite a gradual decline in the insulin secretory 
response to the drug. In addition to its blood glucose lowering actions, GBL produces a 
mild diuresis by enhancement of renal free water clearance. Pharmacokinetics 
parameters are displayed in Table 3. (89)  
 
Glibenclamide 
C23H28ClN3O5S 
Figure 7. GBL chemical structure and molecular formula. 
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Table 3. Pharmacokinetic parameters of GBL. 
 
GBL is a Biopharmaceutics Classification System (BCS) class II compound, i.e., 
low solubility and high permeability, making it a case of interest for studies related to the 
solubility and dissolution enhancement. So, for dissolution enhancement, particle size 
and morphology modifications are the most selected methods, including solid dispersion 
formulations, micronization and nanomization. Solid dispersion formulations between 
GBL and hypromellose, microcrystalline cellulose, polyethylene glycol and other 
polymers have been published extensively in the last decade regarding the improvement 
of dissolution rate. Furthermore, regarding particle size control, nanomization of GBL 
determined, approximately, 10 times higher drug release percentage. However, solid 
dispersion formulations and particle size reduction are limited to a set of APIs because 
they can result in decreased dissolution rate on ageing, caused by moisture absorption 
or phase separation, and in drug degradation. (92–97) 
1.7 – Co-formers 
In this work six different co-formers were tested for co-crystallization of GBL: p-
aminobenzoic (PABA), nicotinamide (NICO), malic acid (MAL), adenine (ADE), D-
mannitol (MAN) and tromethamine (TRIS). Such co-formers for GBL co-crystals were 
selected according to ongoing research works developed at the LAQV/REQUIMTE, 
Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, 
Portugal in collaboration with a second research group from Brazil (Centro de Ciências 
Sociais, Saúde e  Tecnologia,  Universidade  Federal  do  Maranhão,  Imperatriz,  MA, 
Brazil). (29,98,99) 
PABA or p-aminobenzoic acid (Figure 8) is an aminobenzoic acid isomer, which 
combined with pteridine and glutamic acid, forms folic acid and is a vitamin B complex 
Pharmacokinetic 
parameter 
 
Bioavailability 1 
Absorption 
Significant absorption within 1 hour; 
Peak plasma levels are reached in 2 to 4 hours. 
Half-life 
1.4-1.8 hours (unchanged drug); 
10 hours (metabolites included) 
Volume of distribution 
Steady state Vd=0.125 L/kg 
Vd during elimination phase=0.155 L/kg 
Clearance  
78 ml/hr/kg in healthy adults. It may be substantially 
decreased in those with severe renal impairment. 
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member. When PABA is exposed to light, absorbs ultraviolet (UV) light and emits excess 
energy via a photochemical reaction, causing damage to DNA and consequently skin 
cancer. Such DNA defects lead to the withdrawal from the market of sunscreen 
formulations containing PABA. (100,101) 
 
PABA may also increase oxygen uptake, enhancing monoamine oxidase activity 
to promote degradation of serotonin, revealing antifibrotic properties. As a solid, this 
substance appears as a white powder, slightly soluble in water and freely soluble in 
alcohol. (90,100,101)Regarding co-crystals studies, PABA has been successfully tested 
in systems with furosemide, hydrochlorothiazide, carbamazepine, acemetacin, 
niclosamide, ketoconazole and nitrofurantoin. (60,102–107)  
Nicotinamide or NICO (Figure 9) is the active form of vitamin B3 (3-pyridine 
carboxamide) and a component of the coenzyme nicotinamide adenine dinucleotide 
(NAD), which as many pharmacological actions and therapeutic uses. (108–110) 
 
After oral administration, NICO is readily absorbed from the gastrointestinal tract 
and is widely distributed to the body tissues after metabolic conversion into N-methyl 
nicotinamide, 2- pyridone and 4-pyridone derivatives. NICO is primarily used for the 
prevention of deficiency in vitamin B3, which is characterized by skin lesion with 
hyperpigmentation and hyperkeratinisation, diarrhoea, abdominal pain, glossitis, 
stomatitis, loss of appetite, headache, lethargy and mental and neurological 
disturbances. As an API, NICO can also be used as a vasodilator, anti-hyperlipidaemia 
agent it can be useful in the treatment of mild-to-moderate inflammatory acne. (90,108–
Figure 8. PABA molecular structure. 
Figure 9. NICO molecular structure. 
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110). NICO appears as a white crystalline powder or colourless crystals and it is freely 
soluble in water and in dehydrated alcohol. Regarding the co-crystals, NICO has 
successfully been tested in systems with furosemide, aceclofenac, theophylline, 
indomethacin, carbamazepine, naproxen, fenofibrate and gliclazide (90,98,111–117) 
Malic acid or MAL (Figure 10) is an organic dicarboxylic acid, and when on its 
ionized form it`s malate, which is an intermediate of the citric acid (TCA) cycle along with 
fumarate. MAL has been used in trials studying the treatment of xerostomia, depression 
and hypertension. In the pharmaceutical formulation, malic acid s used as an acidifier, 
flavour and as an alternative to citric acid in effervescent powders. MAL is typically used 
with benzoic acid and salicylic acid for desloughing of ulcers, burns and wounds, and 
with arginine in preparations for the treatment of liver disorders. (90,118,119)  
 
Regarding co-crystals studies, MAL has successfully been tested in systems with 
itraconazole, sulfamethoxazole and caffeine.  (40,120,121) 
Adenine or ADE (Figure 11) is one of the components of adenine nucleotides that 
form nucleic acids and it is also a constituent of many coenzymes. ADE has been used 
to manage white blood cell disorders and alcoholism and it is known to prevent loss of 
cell viability of red cells during long-time storage. (90,122,123) 
  
As an API, ADE derivates have significant antiviral and cytostatic activity. So, 
several ADE derivates have been marketed for the treatment of human 
immunodeficiency virus (HIV), hepatitis B virus (HBV), Cytomegalovirus (CMV) and other 
virus-infected diseases. (124,125)As a solid, ADE appears as a white powder, very 
slightly soluble in water and in alcohol. This substance dissolves in dilute mineral acids 
and in dilute solutions of alkali hydroxides. (90) Regarding co-crystals studies, ADE has 
Figure 10. MAL molecular structure. 
Figure 11. ADE molecular structure.  
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been successfully tested in systems with fumaric acid, furosemide, succinic acid, fumaric 
acid and maleic acid. (22,126,127) 
D-Mannitol or MAN (Figure 12) is an alcohol and a sugar, which can be used to 
treat oliguria associated with kidney failure or other manifestations of inadequate renal 
function. MAN is commonly used to increase urine production, being part of the diuretics. 
(128–130)  
 
MAN can also be used to treat or prevent medical conditions that are caused by 
an increase in body fluids/water, being used to open the blood-brain barrier, which allows 
anticancer medicines to enter the brain and treat brain tumours. MAN is frequently given 
along with other diuretics, such as furosemide and chlorothiazide, and/or IV fluid 
replacement. (131) As a solid, MAN appears as a white or almost white crystalline 
powder and it is freely soluble in water and very slightly soluble in alcohol. (90) 
Tromethamine or TRIS (Figure 13) is an organic amine proton acceptor and it has 
several uses in the pharmaceutical industry. TRIS, as an API, can be administered as 
an analgesic, anti-inflammatory and antipyretic, belonging to the pyrrolo-pyrrole group 
on non-steroidal anti-inflammatory drugs (NSAID). (90,132,133) 
 
As an NSAID member, TRIS can inhibit both cyclooxygenase-1 and -2 cascade 
mechanisms, blocking the production of prostaglandins. TRIS can also be used in the 
treatment of metabolic acidosis due to its alkalinizing effect and acts as a weak osmotic 
diuretic, which makes it suitable to administrate during cardiac arrest and cardiac bypass 
surgery. (90,132,133) As a solid, TRIS appears as a white or an almost white crystalline 
powder and it is freely soluble in water, sparingly soluble in alcohol and very slightly 
soluble in ethyl acetate. Regarding co-crystals, TRIS has been used in systems with 
glibenclamide and gliclazide. (90,134,135) 
Figure 12. MAN molecular structure. 
Figure 13. TRIS molecular structure. 
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Chapter 2 – Materials and methods 
2.1 – Materials 
GBL was provided by Generis Farmacêutica S.A.. PABA (>99.5% purity) 
was acquired from Sigma-Aldrich (St. Louis, MO, USA). NICO (>99.5% purity) was 
acquired from Sigma–Aldrich (St. Louis, Missouri). MAL (>99.5% purity) was acquired 
from Merck (Germany). ADE (>99.0% purity) was acquired from Sigma-Aldrich (USA). 
MAN (>99.0% purity) was acquired from Riedel-de-Haën (Germany). TRIS (≥99% purity) 
was acquired from Sigma-Aldrich (St. Louis, MO, USA). Methanol was acquired from 
Sigma-Aldrich® (≥99,8% purity) and ethanol from Carlo Erba, DasitGroup®. 
2.2 – Grinding method  
The co-crystallization experiments were performed in a planetary ball mill PM 100 
from Retsch® with a grinding jar of 50ml, maximum speed of 600rpm and the stainless-
steel grinding balls were also acquired from Retsch® with a diameter of 12mm. (136,137) 
In each experiment, it was placed 1gr of powder (API and respective co-former) and, 
approximately, 800 mg of powder was recovered after grinding due to the adherence to 
the jar walls. 
2.3 – Co-crystals production 
In this work, several experiments where performed by co-crystallizing GBL with the 
six different co-formers (PABA, MAN, ADE, NICO, MAL and TRIS) using a ball mill.  GBL 
co-crystals were synthetized through grinding using a ball mill with no-solvent involved 
but also with ethanol and methanol. GBL co-crystallization was tested with PABA, MAN, 
ADE, NICO, MAL and TRIS. Equimolar quantities of API and co-former (1:1) were used. 
The grinding jar was filled with the grinding balls and with both components and then 
milled for 3 hours with a speed of 600rpm, the maximum allowed by the equipment. 
When using ethanol and methanol to the GBL co-crystallization, two drops were added 
to the grinding jar. In Table 4 all co-crystals systems ratio and respective quantities are 
displayed. 
Table 4. Co-crystals systems ratio and respective quantities. 
Co-crystal 
test 
Ratio GBL PABA MAL MAN TRIS NICO ADE Ethanol Methanol 
GlibPaba 1:1 500mg 137mg - - - - - - - 
GlibPaba 1:1 500mg 137mg - - - - - 2 drops - 
GlibPaba 1:1 500mg 137mg - - - - - - 2 drops 
24 
 
 
2.4 – Characterization Methods 
GBL, co-formers and products obtained by ball milling were characterized by NIR, 
MIR and DSC.  
2.4.1 – Differential scanning calorimetry 
 The thermograms were obtained with a differential scanning calorimeter (TA 
instruments, Q200, USA) purged with nitrogen. For the analysis, approximately 3 mg 
were placed in aluminium non-hermetic crucibles and then heated at a rate of 10°C/min 
from 0ºC to 200ºC (except the GlibAde systems which were heated from 0ºC to 400ºC).  
Table 5. Melting points of all pure compounds.  
Pure compounds Melting Point (ºC) 
Glibenclamide 173 
Adenine 360 
Malic acid 134 
Nicotinamide 129 
p-aminobenzoic acid 189 
Tromethamine 172 
Mannitol 167 
 
GlibMal 1:1 500mg - 134mg - - - - - - 
GlibMal 1:1 500mg - 134mg - - - - 2 drops - 
GlibMal 1:1 500mg - 134mg - - - - - 2 drops 
GlibMan 1:1 500mg - - 182mg - - - - - 
GlibMan 1:1 500mg - - 182mg - - - 2 drops - 
GlibMan 1:1 500mg - - 182mg - - - - 2 drops 
GlibTris 1:1 500mg - - - 121mg - - - - 
GlibTris 1:1 500mg - - - 121mg - - 2 drops - 
GlibTris 1:1 500mg - - - 121mg - - - 2 drops 
GlibNico 1:1 500mg - - - - 122mg - - - 
GlibNico 1:1 500mg - - - - 122mg - 2 drops - 
GlibNico 1:1 500mg - - - - 122mg - - 2 drops 
GlibAde 1:1 500mg - - - - - 135mg - - 
GlibAde 1:1 500mg - - - - - 135mg 2 drops - 
GlibAde 1:1 500mg - - - - - 135mg - 2 drops 
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2.4.2 – Near-infrared spectroscopy 
 To characterize the obtained systems a Fourier-transform near-infrared analyser 
(FTLA2000, ABB, Québec, Canada) was used and it was equipped with an InGaAs 
detector. The measurements of the samples were made in diffuse reflectance mode 
using a powder sampling accessory with a 2 cm diameter window. The background was 
obtained with a reflectance certified material (polytetrafluoroethylene, PTFE). Spectra 
were acquired with a resolution of 8 cm-1 and stored as the average of 64 scans in the 
range between 10.000 and 4.000 cm-1. For each sample, three spectral replicates were 
taken.  
2.4.3 – Mid-infrared spectroscopy 
A Fourier-transform infrared analyser FT-IR Spectrometer Frontier™ (PerkinElmer 
Inc., MA, USA) equipped with an attenuated total reflectance (ATR) accessory was used 
(single relfection diamond crystal). Each spectrum was acquired with a resolution of 4 
cm-1 as the average of 32 scans in the range between 4.000 cm-1 and 600 cm-1. For each 
sample, two spectral replicates were taken. 
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Chapter 3 – Results and discussion 
This chapter presents the analysis for the thermal characterization and 
spectroscopic characterization for each API and co-former system. Furthermore, a 
summary of the characterization results is presented. Firstly, the obtained products 
through grinding were characterized by DSC and by vibrational spectroscopic 
techniques. The possibility of co-crystal formation is discussed for each case based on 
the results of the characterization techniques.  All grinded products were characterized 
by DSC. In this technique, the potential co-crystal was compared with the API, respective 
co-former and physical mixture. Table 6 summarizes the results for the thermal 
characterization of the pure compounds by DSC. 
 
Table 6. Transition temperature and enthalpy variation for the pure compounds used in this 
study.  
Pure 
components 
1st peak 2nd peak 
Tpeak (°C) 
±st.dev. 
∆H (J/g) 
±st.dev. 
Tpeak (°C) 
±st.dev. 
∆H (J/g) 
±st.dev. 
GBL 173.44 ±0.01 -76.42 ±5.07 - - 
ADE 361.46 ±0.00 -117.3 ±12.3 - - 
MAL 134.37 ±0.02 -212.7 ±23.3 - - 
MAN 167.05 ±0.05 -285.0 ±17.0 - - 
NICO 129.78 ±0.00 -190.3 ±11.9 - - 
PABA 188.73 ±0.02 -172.6 ±17.5 - - 
TRIS 142.61 ±0.10 -236.70 ±16.10 172.39 ±0.01 -23.92 ±1.71 
 
Regarding the pure compounds, all of them were thermally characterized by one 
single endothermic peak, corresponding to the melting point, except for TRIS. Such co-
former exhibit an enthalpy variation endothermic peak at 142.61±0.10°C (∆H=-
236.70±16.10 J/g), corresponding to a plastic deformation from a crystalline 
orthorhombic to a body-centred cubic structure, and a second endothermic peak at 
172.39±0.01°C (∆H=-23.92 ±1.71 J/g), which is the melting point. (138) GBL was 
thermally stable up to 173.44±0.01ºC (∆H= -76.42±5.07 J/g), which corresponds to the 
referred temperature value in the literature (169-180ºC).(89,135) Table 7 displays the 
results for the thermal characterization of the physical mixtures (PM) and the milled 
products by DSC. 
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Table 7. Transition temperatures and enthalpy variation for the systems under study and 
respective PM. 
 
1st peak 2nd peak 3rd peak 
Tpeak (°C) 
±st.dev. 
∆H (J/g) 
±st.dev. 
T (°C) 
±st.dev. 
∆H (J/g) 
±st.dev. 
T (g°C) 
±st.dev. 
∆H (J/g) 
±st.dev. 
System GlibAde 
GlibAde PM  172.46 
±0.01 
-60.72 
±2.78 
- - - - 
GlibAde (Sol.: None) 174.63 
±0.00 
-71.14 
±7.75 
- - - - 
GlibAde (Sol.: Ethanol) 171.15 
±0.00 
-57.00 
±4.98 
- - - - 
GlibAde (Sol.: Methanol) 173.46 
±0.00 
47.26 
±1.31 
- - - - 
System GlibMal 
GlibMal PM  
134.91 
±0.01 
-125.6 
±12.8 
142.58 
±0.01 
- - - 
GlibMal (Sol.: None) 
124.52 
±0.26 
- 
131.43 
±0.07 
-25.95 
±5.57 
154.65 
±0.01 
- 
GlibMal (Sol.: Ethanol) 
107.61 
±0.26 
-1.90 
±1.14 
138.89 
±0.34 
-15.38 
±11.3 
157.98 
±0.01 
- 
GlibMal (Sol.: Methanol) 
133.03 
±0.03 
-14.92 
±6.65 
143.65 
±0.30 
- 
159.00 
±0.01 
- 
System GlibMan 
GlibMan PM  166.34 
±0.01 
-1.79 
±1.60 
170.14 
±0.14 
-11.13 
±16.41 
- - 
GlibMan (Sol.: None) 167.15 
±0.01 
-125.3 
±20.8 
- - - - 
GlibMan (Sol.: Ethanol) 168.99 
±0.00 
-96.58 
±23.62 
- - - - 
GlibMan (Sol.: Methanol) 169.04 
±0.00 
-134.0 
±13.4 
- - - - 
System GlibNico 
GlibNico PM  125.43 
±0.03 
-70.25 
±15.11 
139.49 
±0.08 
-2.860 
±1.56 
- - 
GlibNico (Sol.: None) 122.08 
±0.00 
-44.56 
±7.81 
141.82 
±0.02 
-5.306 
±3.33 
- - 
GlibNico (Sol.: Ethanol) 121.45 
±0.01 
-23.94 
±2.14 
157.19 
±0.17 
-23.97 
±9.73 
- - 
GlibNico (Sol.: Methanol) 120.64 
±0.10 
-19.74 
±10.48 
149.12 
±0.13 
-11.42 
±8.58 
- - 
System GlibPaba 
GlibPaba PM  143.61 
±0.10 
-9.08 
±2.37 
- - - - 
GlibPaba (Sol.: None) 61.25 
±0.10 
-2.67 
±1.64 
91.74 
±0.02 
- 
128.08 
±0.00 
-34.46 
±11.72 
GlibPaba (Sol.: Ethanol) 138.56 
±0.00 
-37.27 
±10.1 
172.89 
±0.00 
-0.317 
±0.09 
- - 
GlibPaba (Sol.: Methanol) 139.22 
±0.43 
-22.70 
±10.99 
154.23 
±0.03 
-0.591 
±0.07 
- - 
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System GlibTris 
GlibTris PM  124.86 
±0.00 
-0.834 
±0.01 
137.28 
±0.02 
-154.7 
±19.7 
- - 
GlibTris (Sol.: None) 118.71 
±0.10 
-20.66 
±1.88 
135.43 
±0.01 
-1.15 
±0.10 
140.71 
±0.01 
-6.59 
±0.16 
GlibTris (Sol.: Ethanol) 135.06 
±0.02 
-1.326 
±1.04 
142.42 
±0.00 
-16.34 
±7.52 
- - 
GlibTris (Sol.: Methanol) 133.14 
±0.01 
-2.562 
±1.94 
143.92 
±0.00 
-39.33 
±15.2 
- - 
 
Regarding the spectroscopic characterization, the NIR and MIR spectroscopic 
analysis aims to verify whether there was molecular bond formation between GBL and 
the six co-formers. In this way, by comparison with the PM it is observed if there are new 
or shifted bonds, corresponding to new vibration between GBL and co-formers.  
 
3.1 – GlibAde system  
When analysing the thermograms for the GlibAde (1:1) without solvent, GlibAde 
(1:1) Ethanol and GlibAde (1:1) Methanol systems (Fig. 14) and the values present in 
Table 7, we can verify that all milled systems express a similar behaviour with the PM. 
From the DSC results it can be inferred that no co-crystal was produced in this case. 
Table 7(continuation). Transitions temperature and enthalpy variation for the systems under study and respective PM. 
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Figure 14. Thermograms of the GlibAde system: (a) GlibAde (1:1) without solvent, (b) GlibAde 
(1:1) Ethanol, (c) GlibAde (1:1) Methanol. 
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Figure 15. Spectroscopic characterization: (a) NIR spectra for the pure compound ADE; (b) NIR 
spectra for the pure compound GBL; (c) NIR spectra for the GlibAde PM; (d) NIR spectra for the 
GlibAde(1:1) without solvent; (e) NIR spectra for the GlibAde (1:1) Ethanol and (f) NIR spectra for 
the GlibAde (1:1) Methanol. 
The NIR spectrum of the GlibAde (1:1) system without solvent shows a difference 
in the spectral region (Fig.15): 
• Between 5000-4500 cm-1, which corresponds to the combination region of the 
vibration of the amine (RNH2) and amide (CONH-R); 
The NIR spectrum of the GlibAde (1:1) Ethanol and GlibAde (1:1) Methanol 
systems do not show significant differences.  
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Figure 16. Spectroscopic characterization: (a) MIR spectra for the pure compound ADE; (b) MIR 
spectra for the pure compound GBL; (c) MIR spectra for the GlibAde PM; (d) MIR spectra for the 
GlibAde (1:1) without solvent; (e) MIR spectra for the GlibAde (1:1) Ethanol and (f) MIR spectra 
for the GlibAde (1:1) Methanol. 
The MIR spectrum of the GlibAde (1:1) system without solvent shows differences 
in the spectral region (Fig.16): 
• at ≈ 1020 cm-1 (fingerprint region), which may be due to the stretching of the C-N 
amine vibration; 
• at ≈ 1420 cm-1 (fingerprint region), corresponding to the bending of the C-H in the 
methyl group; 
• at ≈ 1600 cm-1, which may result of the stretching of C=C; 
• at ≈ 1660 cm-1, result of the stretching of C=C. 
The MIR spectrum of the GlibAde (1:1) Ethanol and GlibAde (1:1) Methanol 
systems (Fig. 16) do not show significant differences.  
 
3.2 – GlibMal system  
The GlibMal PM thermogram (Fig. 17) presents an endothermic peak 
corresponding to the eutectic melting following by an exothermic peak that may 
correspond to the co-crystal formation followed by the co-crystal melting. This behaviour 
is consistent with the possibility of co-crystal formation between these two compounds. 
(14) The thermogram of the GlibMal (1:1) system without solvent shows a complex 
behaviour with several endothermic peaks followed by what seems to be an exothermic 
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event. This behaviour can be due to the presence of the co-crystal impure, i.e., in a 
mixture with the pure components, or the presence of different polymorphs of the 
cocrystal.  
The thermogram of the GlibMal (1:1) Ethanol system (Fig. 17b) shows an 
endothermic peak, which may be due to solvent presence, followed by another 
endothermic peak and an exothermic peak. This behaviour is consistent with the 
possibility of co-crystal formation. The thermogram of the GlibMal (1:1) Methanol (Fig. 
17c) system exhibits a desolvation peak at ≈ 65°C, corresponding to the presence of 
methanol in the mixture. The desolvation peak is followed by several endothermic peaks 
and what seems to be an exothermic event. This behaviour is similar to the GlibMal (1:1) 
without solvent system, leading to the conclusion that this behaviour can be due to the 
presence of an impure co-crystal and is consistent with the possibility of co-crystal 
formation. 
 
Figure 17. Thermograms of the GlibMal system: (a) GlibMal (1:1) without solvent, (b) GlibMal (1:1) 
Ethanol, (c) GlibMal (1:1) Methanol. 
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Figure 18. Spectroscopic characterization: (a) NIR spectra for the pure compound MAL; (b) NIR 
spectra for the pure compound GBL; (c) NIR spectra for the GlibMal PM; (d) NIR spectra for the 
GlibMal(1:1) without solvent; (e) NIR spectra for the GlibMal (1:1) Ethanol and (f) NIR spectra for 
the GlibMal (1:1) Methanol. 
 
Concerning the NIR spectrum of the GlibMal system without solvent, differences 
are shown (Fig. 18): 
• between 6000-5900 cm-1, corresponding to the first overtone of the C-H bound in 
the methyl group; 
• between 6900-6650 cm-1, in the second overtone region corresponding to the 
CONH2, CONH-R, NH2 and OH groups vibrations. 
 
The NIR spectra of the GlibMal (1:1) Ethanol and Methanol systems (Fig. 18) 
exhibits the same differences as the GlibMal (1:1) system without solvent, except the 
differences regarding to solvent presence, which is most notable in the system with 
ethanol: 
• at ≈ 5200 and 7000 cm-1, a characteristic band of OH vibration is visible in the 
first overtone region, being due to solvent presence;  
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Figure 19. Spectroscopic characterization: (a) MIR spectra for the pure compound MAL; (b) MIR 
spectra for the pure compound GBL; (c) MIR spectra for the PM GBL:MAL (1:1); (d) MIR spectra 
for the GBL:MAL (1:1) w/solvent; (e) MIR spectra for the GBL:MAL (1:1) Ethanol and (f) MIR 
spectra for the GBL:MAL (1:1) Methanol. 
 
The MIR spectrum of the GlibMal (1:1) system without solvent shows a difference 
(Fig. 19): 
• at ≈ 1690 cm-1, a characteristic vibration band corresponding to the C=O 
stretching.  
Regarding the systems with solvent, the MIR spectrum of the GlibMal (1:1) Ethanol 
(Fig. 19) shows differences: 
• at ≈ 1150 cm-1 (fingerprint region), corresponding to the C=O stretching. 
• at ≈ 3500 cm-1, corresponding to the OH stretching band, which is due to the 
solvent presence;  
In the MIR spectrum of GlibMal (1:1) Methanol system, the observed differences 
for the GlibMal (1:1) Ethanol are also valid for the system with methanol. 
 
3.3 – GlibMan system  
 The GlibMan PM thermogram exhibits two endothermic peaks (Fig. 20), which may 
be due to the pure compounds, because they are close to the respective melting points. 
All systems with MAN exhibit a similar behavior with the PM. Therefore, it can be 
concluded that no co-crystal was formed. 
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Figure 20. Thermograms of the GlibMan system: (a) GlibMan (1:1) without solvent, (b) GlibMan 
(1:1) Ethanol, (d) GlibMan (1:1) Methanol. 
 
 
Figure 21. Spectroscopic characterization: (a) NIR spectra for the pure compound MAN; (b) NIR 
spectra for the pure compound GBL; (c) NIR spectra for the GlibMan PM; (d) NIR spectra for the 
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GlibMan(1:1) without solvent; (e) NIR spectra for the GlibMan (1:1) Ethanol and (f) NIR spectra 
for the GlibMan (1:1) Methanol.  
The NIR spectra of the GlibMan (1:1) system without solvent and GlibMan (1:1) 
Ethanol and Methanol systems (Fig. 21) did not exhibit differences between the samples 
and the PM.  
 
Figure 22. Spectroscopic characterization: (a) MIR spectra for the pure compound MAN; (b) MIR 
spectra for the pure compound GBL; (c) MIR spectra for the GlibMan PM; (d) MIR spectra for the 
GlibMan (1:1) without solvent; (e) MIR spectra for the GlibMan (1:1) Ethanol and (f) MIR spectra 
for the GlibMan (1:1) Methanol. 
Regarding the MIR spectra of the GlibMan (1:1) system without solvent, GlibMan 
(1:1) Ethanol and GlibMan (1:1) Methanol systems (Fig. 22), no differences were found 
between the milled and the physical mixtures of each sample.  
 
3.4 – GlibNico system  
The thermograms of the GlibNico (1:1) system without solvent and GlibNico (1:1) 
Ethanol and Methanol exhibit one endothermic peak followed by another endothermic 
peak (Fig. 23). This behaviour is consistent with the melting of the pure compounds, 
therefore, there was no co-crystal formation.  
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Figure 23. Thermograms of the GlibNico system: (a) GlibNico (1:1) without solvent, (b) GlibNico 
(1:1) Ethanol, (d) GlibNico (1:1) Methanol. 
 
 
Figure 24. Spectroscopic characterization: (a) NIR spectra for the pure compound NICO; (b) NIR 
spectra for the pure compound GBL; (c) NIR spectra for the GlibNico PM; (d) NIR spectra for the 
GlibNico (1:1) without solvent; (e) NIR spectra for the GlibNico (1:1) Ethanol and (f) NIR spectra 
for the GlibNico (1:1) Methanol. 
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The NIR spectra for GlibNico (1:1) system without solvent and GlibNico (1:1) 
Ethanol and Methanol systems (Fig. 24), only exhibit in the combination region, at ≈ 4850 
cm-1, a vibration band of the OH group, however, it is due to traces of water in the physical 
mixture sample.  
 
 
Figure 25. Spectroscopic characterization: (a) MIR spectra for the pure compound NICO; (b) MIR 
spectra for the pure compound GBL; (c) MIR spectra for the GlibNico PM; (d) MIR spectra for the 
GlibNico (1:1) without solvent; (e) MIR spectra for the GlibNico (1:1) Ethanol and (f) MIR spectra 
for the GlibNico (1:1) Methanol. 
 
In the MIR spectrum of the GlibNico (1:1) system without solvent and GlibNico (1:1) 
Ethanol and Methanol systems (Fig. 25), no differences between the milled mix and the 
physical mixture were found.  
 
 
3.5 – GlibPaba system  
The thermograms of the GlibPaba (1:1) Ethanol and Methanol display two 
endothermic peaks, one followed by the other (Fig. 26). This behaviour is consist to the 
melt of the pure compounds, therefore, no co-crystal was formed. (14) The thermogram 
of the GlibPaba (1:1) system without solvent (Fig. 26) exhibits an endothermic peak 
followed by an exothermic peak and after another endothermic peak. The first 
endothermic peak may the melt of a co-crystal polymorph, followed by what seems to be 
the formation of a second polymorph and followed by the melt of the second polymorph. 
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This behaviour is consistent with the possibility of co-crystal formation between these 
two compounds. 
 
Figure 26. Thermograms of the GlibPaba system: (a) GlibPaba (1:1) without solvent, (b) GlibPaba 
(1:1) Ethanol, (c) GlibPaba (1:1) Methanol. 
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Figure 27. Spectroscopic characterization: (a) NIR spectra for the pure compound PABA; (b) NIR 
spectra for the pure compound GBL; (c) NIR spectra for the GlibPaba PM(1:1); (d) NIR spectra 
for the GlibPaba (1:1) without solvent; (e) NIR spectra for the GlibPaba (1:1) Ethanol and (f) NIR 
spectra for the GlibPaba (1:1) Methanol. 
  
In the NIR spectrum of the GlibPaba (1:1) system without solvent (Fig. 27), several 
differences are visible: 
• between 5000-4450 cm-1, in the combination region band corresponding to the 
C-H vibration of the methyl group and amine group; 
• at ≈ 4950 cm-1, corresponding to the amine group vibration in the combination 
group; 
• at ≈ 5100 cm-1, which is due to the amide vibration in the first overtone region; 
• at ≈ 5200 cm-1, corresponding to the carboxylic acid group vibration in the first 
overtone region; 
• at ≈ 6700 cm-1, which corresponds to the second overtone region, in which is 
exhibit vibrations of the amine, amide and OH groups; 
• between 7000-6500 cm-1, corresponding to the second overtone of the CH bound 
and the alcohol (ROH) vibration band; 
• between 9000-8500 cm-1, which is due to the second overtone of the CH bound 
and the amine (RNH2) vibration band. 
In the NIR spectrum of the GlibPaba (1:1) Ethanol and GlibPaba (1:1) Methanol 
systems (Fig. 27), no significant differences were observed.  
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Figure 28. Spectroscopic characterization: (a) MIR spectra for the pure compound PABA; (b) MIR 
spectra for the pure compound GBL; (c) MIR spectra for the GlibPaba PM (1:1); (d) MIR spectra 
for the GlibPaba (1:1) without solvent; (e) MIR spectra for the GlibPaba (1:1) Ethanol and (f) MIR 
spectra for the GlibPaba (1:1) Methanol. 
 
Regarding the MIR spectrum of GlibPaba (1:1) system without solvent (Fig. 28), it 
shows differences between the milled mix and the physical mixture: 
• at ≈ 1170 cm-1, which corresponds to the carboxylic acid C=O stretching vibration; 
• at ≈ 1290 cm-1, corresponding to the C=O of the carboxylic acid stretching 
vibration band; 
• at ≈ 1600 cm-1, which is due to N-H vibration of the amine group and C=C from 
the aromatics stretching vibration bands.  
In the MIR spectrum of the GlibPaba (1:1) Ethanol and GlibPaba (1:1) Methanol 
systems (Fig. 28), no significant differences were observed.  
 
 
3.6 – GlibTris system  
Taking into account a previous study in which this particular system was studied 
through solvent evaporation, the respective thermogram showed a single and well-
defined endothermic peak at ≈144°C, corresponding to the co-crystal melting point (Fig. 
29). (29) However, in this work the GlibTris systems do not display a single endothermic 
peak. The thermogram of the GlibTris (1:1) system without solvent shows a complex 
behaviour with three endothermic peaks. The third endothermic peak, displayed at 
140.71°C, happens in a similar temperature to the one reported in the previous study. 
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This behaviour can be due to the presence of the co-crystal impure, i.e., in a mixture with 
the pure components, or the presence of different polymorphs of the cocrystal. The 
thermograms of the GlibTris (1:1) Ethanol and Methanol (Fig. 29) exhibit two 
endothermic peaks, the same behaviour as the PM. The second endothermic peak in 
both GlibTris (1:1) solvent systems and PM is exhibit in a temperature near to the 
reported temperature in the previous study. This can be due to the presence of the co-
crystal impure; however, the co-crystal formation seems to be possible.   
 
Figure 29. Thermograms of the GlibTris system: (a) GlibTris (1:1) without solvent, (b) GlibTris 
(1:1) Ethanol, (d) GlibTris (1:1) Methanol. 
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Figure 30. Spectroscopic characterization: (a) NIR spectra for the pure compound TRIS; (b) NIR 
spectra for the pure compound GBL; (c) NIR spectra for the GlibTris PM; (d) NIR spectra for the 
GlibTris (1:1) without solvent; (e) NIR spectra for the GlibTris (1:1) Ethanol and (f) NIR spectra for 
the GlibTris (1:1) Methanol. 
  
In the NIR spectrum of the GlibTris (1:1) system without solvent (Fig. 30), some 
differences were found:  
• at ≈ 4400 and ≈ 4450 cm-1, which corresponds to the CHO group vibration band 
in the combination region; 
• at ≈ 4500 and ≈ 4550 cm-1, corresponding to the CHO group vibration and the 
amine vibration in the combination region; 
• at ≈ 4900 cm-1, in the first overtone region is it exhibit differences regarding the 
amide vibration; 
• at ≈ 5200 cm-1, which corresponds to H2O in the first overtone region and leading 
to the conclusion that this sample contained water; 
• at ≈ 6900 cm-1, it is exhibit, in the second overtone, region an amide group 
vibration.  
According to the paper published with this system, the differences found in this 
work correspond to the differences referred in that article. Although the wavenumbers 
may differ, the vibration bands are the same, which may imply the co-crystal formation. 
(29) 
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The NIR spectra of the GlibTris (1:1) Ethanol and Methanol systems (Fig. 30) do 
not exhibit significant differences between the PM and the milled systems. However, two 
differences are shown in both Ethanol and Methanol spectra: 
• at ≈ 4450 cm-1, which corresponds to the CHO group vibration band in the 
combination region; 
• at ≈ 4600 cm-1, corresponding to the CHO group vibration and the amine vibration 
in the combination region. 
 
Figure 31. Spectroscopic characterization: (a) MIR spectra for the pure compound TRIS; (b) MIR 
spectra for the pure compound GBL; (c) MIR spectra for the GlibTris PM; (d) MIR spectra for the 
GlibTris (1:1) without solvent; (e) MIR spectra for the GlibTris (1:1) Ethanol and (f) MIR spectra 
for the GlibTris (1:1) Methanol. 
 
The MIR spectrum of the GlibTris (1:1) system without solvent (Fig. 31), the 
fingerprint region displays several differences:  
• at ≈ 750 cm-1 and ≈ 1700 cm-1, it is displayed two vibrations bands corresponding 
to the primary amine (NH) wagging and bending vibrations, respectively;  
• at ≈ 800 cm-1 and ≈ 1250 cm-1, corresponding to two vibration stretches 
characteristic of amine vibrations; 
• at ≈ 1050 cm-1, which corresponds to the C-N stretching vibration band from the 
amine group; 
• at ≈ 3250 cm-1 and ≈ 3400 cm-1, two amine stretching vibrations are exhibit in the 
spectra region. 
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According to the reported article referring this system, the differences found in this 
work correspond to the differences referred in the same article. Although the 
wavenumbers may differ and the fact that above the wavenumber of 3000 cm-1 no 
differences were observed, the vibration bands observed are the same, which may imply 
the co-crystal formation. (29) 
The MIR spectrum of the GlibTris (1:1) Ethanol system (Fig. 31), shows several 
differences in the fingerprint region:  
• at ≈ 850 cm-1 and ≈ 1600 cm-1, it is displayed two vibrations bands corresponding 
to the primary amine (NH) wagging and bending vibrations, respectively; 
• at ≈ 1050 cm-1 and ≈ 1100 cm-1, which corresponds to the C-N stretching vibration 
band from the amine group; 
• between 1400-1350 cm-1 spectra region, corresponding to alkane bending 
vibration characteristic band. 
The MIR spectrum of the GlibTris (1:1) Methanol system (Fig. 31), it expresses 
several differences in the fingerprint region:  
• at ≈ 850 cm-1 and ≈ 1600 cm-1, it is displayed two vibrations bands corresponding 
to the primary amine (NH) wagging and bending vibrations, respectively; 
• at ≈ 1100 cm-1, which corresponds to the C-N stretching vibration band from the 
amine group; 
• between 1400-1350 cm-1 spectra region, corresponding to alkane bending 
vibration characteristic band. 
 
3.3 – Summary of the characterization results 
 All the mentioned characterization methods were valuable tools to determine if a 
co-crystal was formed (or not) and each one gave different insights over the co-
crystallization process and product. For the analysis of whether a co-crystal was formed 
or not, the milled product characteristics were compared to the pure API (GBL), the pure 
co-former and the physical mixture of both. Table 8 summarizes the conclusions 
withdrawn from the characterization results, i.e., whether there were differences 
observed between the milled mixture and the respective physical mixture. 
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Table 8. Summary of the conclusion from the characterization methods. (YES= differences 
found; NO= differences not found) 
 DSC MIR NIR 
GlibAde system 
GlibAde (1:1) without solvent No Yes Yes 
GlibAde (1:1) Ethanol  No No No  
GlibAde (1:1) Methanol No No No 
GlibMal system 
GlibMal (1:1) without solvent Yes Yes Yes 
GlibMal (1:1) Ethanol  Yes Yes Yes 
GlibMal (1:1) Methanol Yes Yes Yes 
GlibMan system 
GlibMan (1:1) without solvent No No No 
GlibMan (1:1) Ethanol  No No No 
GlibMan (1:1) Methanol No No No 
GlibNico system 
GlibNico (1:1) without solvent No No No 
GlibNico (1:1) Ethanol  No No No 
GlibNico (1:1) Methanol No No No 
GlibPaba system 
GlibPaba (1:1) without solvent Yes Yes Yes 
GlibPaba (1:1) Ethanol  No No No 
GlibPaba (1:1) Methanol No No No 
GlibTris system 
GlibTris (1:1) without solvent Yes Yes Yes 
GlibTris (1:1) Ethanol  Yes Yes Yes 
GlibTris (1:1) Methanol Yes Yes Yes 
 
To further solidify the analysis performed previously and presented in Table 8, a 
mathematical calculation was performed (in Matlab) to evaluate differences obtained in 
infrared spectra. The goal was to identify differences between the spectrum of a mixture 
(GLB and co-former) and the milling product, highlighting the possibility of the production 
of a new form. The idea was based on the fact that, for both MIR and NIR, a spectrum 
of a mixture can be reconstructed from the spectra of the pure components. Basically, 
the spectrum of a mixture can be estimated from a linear combination of the pure 
components spectra. However, because the co-crystal evidence differences from a 
spectrum of a pure mixture, the reconstruction from the pure components spectra should 
be more difficult (and therefore present a higher reconstruction error). Therefore, an 
algorithm was constructed for the optimal reconstruction of spectra of mixtures and 
potential cocrystals from pure components spectra. The difference between the 
reconstruction and the experimental spectrum reveals the ability or not of the 
reconstruction. The results presented below compare the result of the best possible 
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reconstruction (always a linear combination of the pure components spectra) with the 
experimental spectra for FTIR and FTNIR. 
In Table 8, regarding the GlibAde system without solvent, it is showed that no 
differences were found in the DSC thermogram; however, differences were found when 
analysing the NIR and MIR spectra. This is in accordance with the results showed in 
Figure 32, i.e., both NIR and MIR experimental spectra cannot be reconstructed from the 
original spectra of GBL and ADE. This leads to the conclusion that a different compound 
was formed, although it was not detected in the DSC. It is however unclear the reason 
for this difference. The new compound may not even be a co-crystal. 
 
Figure 32. Results obtained for the GlibAde system without solvent using the mathematical model. 
 
The GlibAde Ethanol and Methanol systems did not show differences in the DSC 
thermogram and in the NIR and MIR spectra. When analysing the results from the 
mathematical reconstruction (Fig. 33 and 34) it is observed that the experimental NIR 
and MIR spectra can be built from its precursors (GBL and ADE) by using the 
mathematical model. Therefore, it is possible to conclude that these systems were not 
successful and that the result of the grinding method was just a combination of both 
original crystals.  
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Figure 33. Results obtained for the GlibAde Ethanol system using the mathematical model. 
 
 
Figure 34. Results obtained for the GlibAde Methanol system using the mathematical model. 
The co-crystallization process with GBL and co-former MAL is a promising system 
because differences were observed in the thermal characterization method and in the 
vibrational spectroscopy characterization methods (Table 8). Moreover, when analysing 
the spectra obtained through the mathematical reconstruction (Fig. 35, 36 and 37) it is 
possible to verify that the experimental NIR and MIR spectra cannot be estimated 
accurately from the original GBL and MAL spectra. However, it should be noted that both 
NIR and MIR physical mixture spectra cannot be reconstructed through the original 
spectra of GBL and MAL, which may indicate an interaction between these two 
compounds even before they are milled. 
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Figure 35. Results obtained for the GlibMal system without solvent using the mathematical model. 
 
Figure 36. Results obtained for the GlibMal Ethanol system using the mathematical model. 
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Figure 37. Results obtained for the GlibMal Methanol system using the mathematical model. 
 
By analysing the summary results (Table 8) for the GlibMan systems, it is possible 
to conclude that this system was not successful because it did not exhibit any differences 
regarding the DSC thermograms and the NIR and MIR spectra, both for the system 
without solvent and for ethanol and methanol systems. Furthermore, when analysing the 
spectra obtained through the mathematical model (Fig. 38, 39 and 40) it is possible to 
verify that the experimental NIR and MIR spectra can be reconstructed from the original 
GBL and MAN spectra. Therefore, these systems without solvent and with ethanol and 
methanol are not successful as a co-crystallization process.  
 
 
Figure 38. Results obtained for the GlibMan system without solvent using the mathematical 
model. 
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Figure 39. Results obtained for the GlibMan Ethanol system using the mathematical model. 
 
Figure 40. Results obtained for the GlibMan Methanol system using the mathematical model. 
 
In Table 8, for the GlibNico systems, it is possible to conclude that this system was 
not successful because it did not exhibit any differences regarding the DSC thermograms 
and the NIR and MIR spectra. Moreover, when analysing the spectra obtained through 
the mathematical reconstruction (Fig. 41, 42 and 43) it is possible to verify that the 
experimental NIR and MIR spectra can be estimated from the original GBL and NICO 
spectra. Therefore, these systems without solvent and with ethanol and methanol are 
not successful regarding the co-crystallization process. It is noteworthy that in the NIR 
spectra for all systems, differences between experimental and adjusted spectra are 
found. However, these differences are due to traces of water in the physical mixture. 
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Figure 41. Results obtained for the GlibNico system without solvent using the mathematical 
model. 
 
Figure 42. Results obtained for the GlibNico Ethanol system using the mathematical model. 
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Figure 43. Results obtained for the GlibNico Methanol system using the mathematical model. 
The co-crystallization process with GBL and PABA without solvent is a promising 
system because differences were observed in the thermal characterization method and 
in the vibrational spectroscopy characterization methods (Table 8). Moreover, when 
analysing the spectra obtained through the mathematical model (Fig. 44) it is possible to 
verify that the experimental NIR and MIR spectra cannot be reconstructed from its 
precursors.  
 
 
Figure 44. Results obtained for the GlibPaba system without solvent using the mathematical 
model. 
The GlibPaba Ethanol and Methanol systems did not show differences in the DSC 
thermogram and in the NIR and MIR spectra. When analysing the results from the 
mathematical model (Fig. 45 and 46) it is observed that the experimental NIR and MIR 
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can be built from its precursors (GBL and PABA) by using the mathematical model. 
Therefore, it is possible to conclude that these systems were not successful.  
 
 
Figure 45. Results obtained for the GlibPaba Ethanol system using the mathematical model. 
 
Figure 46. Results obtained for the GlibPaba Methanol system using the mathematical model. 
 
The co-crystallization process with GBL and TRIS is a promising system since 
differences were observed in the thermal characterization method and in the vibrational 
spectroscopy characterization methods (Table 8). In addition, the mathematical model 
for the reconstruction of the NIR and MIR spectra of the physical mixtures (Fig. 47, 48 
and 49) can reconstruct it from the precursors. However, upon rebuilt of the NIR and MIR 
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spectra of the milled products, the mathematical model fails, reporting to the fact that a 
co-crystal was formed. In this way, we conclude that this system was a success. 
 
 
Figure 47. Results obtained for the GlibTris system without solvent using the mathematical model. 
 
Figure 48. Results obtained for the GlibTris Ethanol system using the mathematical model. 
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Figure 49. Results obtained for the GlibTris Methanol system using the mathematical model. 
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Chapter 4 – Conclusions and future perspectives 
4.1 – Conclusions 
The work involved the GBL co-crystallization process with six different co-formers 
(ADE, MAL, MAN, NICO, PABA and TRIS). 
 
It was concluded that both systems involving mannitol and nicotinamide did not 
form any cocrystals after grinding in the ball mill. On the other hand, relatively to the 
system with adenine, it presented unsatisfactory results when using solvent (ethanol and 
methanol). However, for the system without solvent, the characterization by NIR and MIR 
revealed certain differences, implying the formation of a new compound. The system 
with glibenclamide and p-aminobenzoic acid presented similar conclusions to the system 
with glibenclamide and adenine, both systems with solvent had unsatisfactory results, 
i.e., no co-crystal was formed. For the system without solvent, there was co-crystal 
formation. Finally, the systems with malic acid and tromethamine co-formers presented 
results consisting to co-crystals formation in all cases. The system with glibenclamide 
and malic acid formed co-crystals for the three cases analysed, i.e., without solvent, with 
ethanol and with methanol, as well as the system involving tromethamine. In this way, it 
can be concluded that these two systems were the most satisfactory ones. 
 
4.2 – Future perspectives  
In what concerns the systems in which co-crystals were potentially obtained, the 
purity of must be assessed. For all systems in which co-crystals were not obtained or 
results were inconclusive, more experiments should be performed. These experiments 
should involve changing the ball mill rotation speed, number and size of milling spheres, 
milling time, and stoichiometry. Additionally, evaluating the impact of these process 
conditions towards the formation of co-crystals (purity and yield) is of upmost importance 
for the establishment of design-spaces crucial for process understanding, optimization, 
scaling up procedures and consistent manufacturing (reduced process variability). 
Additionally, products should be further analysed by powder X-Ray diffraction in order to 
validate the formation of co-crystals. Finally, solubility studies should be carried out in 
order to evaluate the changes in properties like the solubility (also the dissolution rate) 
and stability, the first ultimately the purpose of the production of pharmaceutical co-
crystals. 
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